Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Insiders Are Dumping These 10 Healthcare Stocks

In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks.

Healthcare-focused investors were nervous when 2024 started, since election years usually do not bode well for the healthcare industry amid policy-related uncertainties. But healthcare stocks are performing exceptionally well this year, defying all skepticism. The S&P 500 Health Care has gained about 8.3% so far this year, compared to the 10.6% jump in the broader S&P 500 index. A latest report by the Wall Street Journal, quoting data from Dow Jones, said that this has been the best start for the healthcare sector since 2017. Part of the reason why healthcare stocks are growing is the huge gains posted by companies making GLP-1 drugs for weight loss and diabetes. Eli Lilly And Co (NYSE:LLY)’s obesity drug Zepbound is reportedly seeing a huge demand, causing a severe shortage across the US. The company is also behind Mounjaro, an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Eli Lilly And Co (NYSE:LLY) shares have gained about 31% so far this year.

Eli Lilly And Co (NYSE:LLY)’s management talked in detail about the company’s diabetes and obesity drugs along with its future plans during Q4 earnings call:

“This year, we’re planning to initiate a Phase III program in Type 2 diabetes for retatrutide, complementing the ongoing trials in obesity and related complications. Also this year, we are planning to initiate a Phase III program for Lepodiserin, our LPA-lowering siRNA therapy in cardiovascular disease. On Tirzepatide, we’re looking forward to a number of additional key data readouts this year. Beyond SYNERGY-NASH, we expect to see results from the Phase III obstructive sleep apnea and Phase III heart failure studies this year. We note increased investor interest in the timing of SURPASS-CVOT, and we reiterate that we expect the data in 2025, notwithstanding the clinicaltrials.gov listing which will be updated soon to reflect our current assumptions based on event rate.

By the end of 2024, we expect to have results of SURMOUNT 5, which is our head-to-head study of Tirzepatide compared to high-dose semaglutide in participants with obesity. We also expect the full Phase III program readout on our weekly basal insulin, insulin efsitora alfa alpha later this year.”

Read the entire earnings call transcript here.

Denmark-based Novo Nordisk A/S (NYSE:NVO) is also making waves in the industry with its own diabetes and weight loss treatments, Ozempic and Wegovy. Novo Nordisk A/S (NYSE:NVO) jumped earlier this month after the company said that a Phase 1 trial of its Amycretin treatment demonstrated weight loss of 13% after 12 weeks, compared to 6% weight loss patients experienced after 12 weeks in a Wegovy trial.

Novo Nordisk A/S (NYSE:NVO) shares have gained about 25% this year through March 28.

Healthcare and biotech stocks are also seeing a boost amid hopes of rate cuts. When rates are low, healthcare and biotech companies go into expansion mode. There’s already a lot of activity in company pipelines. The WSJ reported that the FDA approved 55 new drugs last year, a significant increase from its 10-year average of 46 drugs.

Despite this optimism, there are some healthcare stocks that recently saw insider selling activity. In this article we will take a look at these companies.

Luis Louro / shutterstock.com

Methodology

For this article, we first used Insider Monkey’s insider trading stock screener and listed healthcare stocks that saw insider selling over the past three weeks. From these companies we picked 10 stocks which saw the biggest insider selling transactions in terms of dollar value. But why is it important to keep tabs on hedge fund and insider activity? Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here).

10. Healthequity Inc (NASDAQ:HQY)

Number of Hedge Fund Investors: 18

Healthequity provides financial and technology solutions in the healthcare industry. Healthequity Inc’s (NASDAQ:HQY) CEO Jon Kessleron on March 22 sold 33,765 shares of Healthequity Inc (NASDAQ:HQY) at $79.81 per share. Since then the stock price is almost flat.

As of the end of the fourth quarter of 2023, 18 hedge funds had stakes in Healthequity Inc (NASDAQ:HQY).

Wasatch Core Growth Fund stated the following regarding HealthEquity, Inc. (NASDAQ:HQY) in its fourth quarter 2023 investor letter:

“Another weak position in the Fund was HealthEquity, Inc. (NASDAQ:HQY), the largest U.S. non-bank custodian for health savings accounts (HSAs). Along with offering HSAs, the company also facilitates employer-sponsored lifestyle and commuter benefits, which include fitness classes, parking programs and transit passes. The stock was down because investors looked ahead to an environment of lower interest rates when the company would earn less income from money held on deposit for customers. While lower rates are a small headwind for HealthEquity, its business model is structured so that the near- to mid-term impact is negligible and more than offset by the continued long-term growth of its entire platform. Given our confidence in HealthEquity, we added to our position on stock-price weakness.”

9. Progyny Inc (NASDAQ:PGNY)

Number of Hedge Fund Investors: 28

Fertility-related solutions and benefits company Progyny Inc (NASDAQ:PGNY) is one of the healthcare stocks with recent insider selling activity. David Schlanger, the Executive Chairman of Progyny Inc (NASDAQ:PGNY), on March 21 dumped 5,826 shares of Progyny Inc (NASDAQ:PGNY) at $37.74. Progyny Inc’s (NASDAQ:PGNY) CFO Mark Livingston also sold 8,222 shares of Progyny Inc (NASDAQ:PGNY) on March 1 at $36.67 per share. Since this transaction the stock has increased by 2.83%.

During its Q4 earnings call last month, the company talked about guidance:

“Looking forward, we expect a mid-70% conversion of full-year adjusted EBITDA to operating cash flow, excluding the impact of any cash taxes. As of December 31, we had total working capital of approximately $454 million reflecting $371 million of cash, cash equivalents and marketable securities and no debt. Finally, turning now to our expectations for the first quarter and the full-year 2024. For revenue, we are projecting between $285 million to $292 million in the first quarter, which contemplates the $15 million headwind in treatment mix shift that, Pete, described to you a little bit earlier. With the visibility that we have into more recent activity, we can see that mix is trending more consistent to what we’d expect, and we’ve reflected that in our guidance over the balance of the year.

For 2024, we project revenue of between $1.285 billion to $1.315 billion reflecting growth of between 18% and 21%. Turning to profitability. We expect between $49 million to $51 million in adjusted EBITDA in the first quarter along with net income of between $12.4 million to $13.7 million.”

Read the entire earnings call transcript here.

Polen Global SMID Company Growth Strategy made the following comment about Progyny, Inc. (NASDAQ:PGNY) in its Q3 2023 investor letter:

“We bought a new position in Progyny, Inc. (NASDAQ:PGNY), a company owned in our U.S. strategies for some time. They are a leading provider of fertility benefit solutions, and through their differentiated approach, their clients can pursue the most effective treatment and achieve optimal outcomes. We believe the company has only a mid-single digit share of its potential total addressable market and is the most dominant player within the fast-growing managed care category. They are already profitable, earn high returns on incremental capital, and have plenty of runway to grow top-line growth as they continue to win new clients and add new services.”

8. Exelixis Inc (NASDAQ:EXEL)

Number of Hedge Fund Investors: 33

Genomics-based drug discovery company Exelixis Inc (NASDAQ:EXEL) ranks eighth in our list of the healthcare stocks with recent insider selling activity. Alan M. Garber, a board member at Exelixis Inc (NASDAQ:EXEL), on March 21 sold 19,205 shares of Exelixis Inc (NASDAQ:EXEL) at $24.01 per share. Patrick J Haley, the EVP Commercial at Exelixis Inc (NASDAQ:EXEL), also dumped about 47,000 shares of Exelixis Inc (NASDAQ:EXEL) at $21.45 per share on March 23. Since March 21 the stock is down 1.3%.

While EXEL saw insider selling, major companies like Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) are seeing an increased interest from both insiders and hedge funds.

7. Blueprint Medicines Corp (NASDAQ:BPMC)

Number of Hedge Fund Investors: 33

Blueprint Medicines Corp (NASDAQ:BPMC) ranks seventh in our list of the healthcare stocks with latest insider selling activity. Jeffrey Albers, a director at Blueprint Medicines Corp’s (NASDAQ:BPMC) board, on March 7 sold 11,033 shares of Blueprint Medicines Corp (NASDAQ:BPMC) at $90.69 per shares. Since then the stock is down 2.6%.

As of the end of the fourth quarter of 2023, 33 hedge funds had stakes in Blueprint Medicines Corp (NASDAQ:BPMC), up from 25 hedge funds in the previous quarter. Unlike Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY), BPMC is a small company that is seeing insider selling.

6. Arcellx Inc (NASDAQ:ACLX)

Number of Hedge Fund Investors: 33

Arcellx Inc (NASDAQ:ACLX) works on treatments for cancer and autoimmune diseases. Jill Carroll, a director at Arcellx Inc’s (NASDAQ:ACLX) board, on March 21 sold 504,263 shares of Arcellx Inc (NASDAQ:ACLX) at $70.55 per share. Since then the stock is down 2.6%. The director also conducted massive selling of the stock last year.

Click to continue reading and see Insiders Are Dumping These 5 Healthcare Stocks.

 Suggested Articles:

Disclosure. None. Insiders Are Dumping These 10 Healthcare Stocks is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!